Other treatment options for patients with T2D such as metformin, glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors, pioglitazone, and sodium-glucose co-transporter-2 inhibitors show in contrast beneficial effects in reducing the risk of hypoglycemia [56]. This evidence concerns the gene GLP1R and Hypoglycemia.